The Antibiotic Resistance Market to be floored by Growing intolerance towards Antibiotics

Date : Aug 25, 2021 Author : PMR Editorial Staff Category : Healthcare

Persistence Market Research states that the global antibiotics resistance market will witness a CAGR of 4% between 2021 and 2031.

The market players are seeking the QIDP (Qualified Infectious Disease Product) designation. This, in turn, does expedite the process of clinical reviewing, thereby extending exclusivity period pertaining to novel generation antibiotics having strong therapeutic value. This factor is expected to impart authenticity to the antibiotic resistance market.

The Way the antibiotic resistance market goes about

The global antibiotic resistance market, by drug class, spans β-Lactam Antibiotics, Caphalosporin, Quinolones Antibiotics, Macrolide Antibiotics, Tatracycline, Oxazolidinones, and others. Pathogen-wise, it’s Staphylococcus aureus, Streptococcus pneumonia, Neisseria gonorrhoeae, Enterococcus faecium, Escherichia coli, Klebsiella pneumonia, Shigella, Clostridium difficile, and likewise.

Disease-wise, CABP (Community Acquired Bacterial Pneumonia), HABP/VABP (Hospital Acquired Bacterial Pneumonia/Ventilator, cUTI (Complicated Urinary Tract Infection), cIAI (Complicated Intra-Abdominal Infections), BSI (Blood Stream Infections), Abdominal Infection and Diarrhea, ABSSSI (Acute Bacterial Skin and Skin Structure Infections), and Drug Resistant Gonorrheae. By mechanism of action, it’s cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis Inhibitors, and others. By distribution channel, it’s retail pharmacies, online pharmacies, and hospital pharmacies. Life sciences and healthcare industries need to collaboratively address this threat sooner than later.


North America holds the largest market share due too various new drugs being launched in lines with new-fangled therapies. Europe stands second on this count. Greece, Italy, and Portugal are amongst the highest consumers of antibiotics all over. As such, they are expected to lead the antibiotics resistance market going forward. The Asia-Pacific, though high on usage of antibiotics as of now, is expected to dominate in terms of antibiotics resistance in the years to come.

By Competition

The key participants in the antibiotic resistance market include Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson, Baxter Healthcare Corporation, Zydus Cadilla, Teva Pharmaceutical Industries Ltd., Novartis AG, Dr. Reddy’s Laboratories Ltd., Mayne Pharma Group Limited, Sun Phharmaceutical Industries Ltd., Cipla Inc., Shanghai Pharmaceutical Group Co., Ltd., and Abbott Laboratories.

Coming to developments on the whole, Fresenius Kabi Group, in 2019, came up with patient awareness program as well as online awareness portal to cater to hospital acquired infections. In the same year, Sandoz did announce agreement for acquiring Japanese operations and the assets associated with it, thereby strengthening the foothold in the market.

The Moves Ahead

There are efforts being made to combat side-effects caused due to excessive dosage of antibiotics. Plus, the proliferation of multi-drug resistant pathogens is there to stay. These factors will cause antibiotic resistance market to flourish in the upcoming period.